News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Utrecht University Study Indicates that Rexahn's Zoraxel(TM) Could Become New-Class of Drug for Treating Sexual Dysfunction


5/12/2009 11:00:46 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), today announced the results of an animal study that further demonstrates Zoraxel as a potential new-class of therapeutic for the effective treatment of sexual dysfunction.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES